1996
DOI: 10.1182/blood.v88.12.4534.bloodjournal88124534
|View full text |Cite
|
Sign up to set email alerts
|

Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia

Abstract: Myelofibrosis with myeloid metaplasia ("M)is a myeloproliferative disorder characterized by clonal expansion of hematopoiesis and marrow fibrosis. Previous results from our group have shown an increased production of t w o potent fibrogenic factors also involved in the regulation of primitive hematopoietic cells, namely transforming growth factor-p1 (TGF-p1) and basic fibroblast growth factor (bFGF), in patients with MMM. It is likely t o assume that the myeloproliferation characteristic of this disease may re… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
44
0

Year Published

1998
1998
2018
2018

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 110 publications
(45 citation statements)
references
References 47 publications
1
44
0
Order By: Relevance
“…Interestingly, studies of haemopoietic pathologies and leukaemias have shown abnormalities in TGFb signalling activity in both early myeloid leukaemia [19], and lymphocytic leukaemia [20]. In CML, the oncogenic Bcr-Abl fusion protein drives haemopoietic cell transformation, and also sustains a rare cohort of quiescent Bcr-Abl+ haemopoietic progenitor cells that persist throughout the CML-CP [21].…”
Section: Discussionmentioning
confidence: 99%
“…Interestingly, studies of haemopoietic pathologies and leukaemias have shown abnormalities in TGFb signalling activity in both early myeloid leukaemia [19], and lymphocytic leukaemia [20]. In CML, the oncogenic Bcr-Abl fusion protein drives haemopoietic cell transformation, and also sustains a rare cohort of quiescent Bcr-Abl+ haemopoietic progenitor cells that persist throughout the CML-CP [21].…”
Section: Discussionmentioning
confidence: 99%
“…Receptors for FGFs have been found on K562 cells (Allouche, 1995;Liuzzo and Moscatelli, 1996) and on CD34 hematopoietic progenitor cells (Berardi et al, 1995;Le Bousse-Kerdil Á es et al, 1996;Testa et al, 1996;Burger et al, 1998Burger et al, , 1999 and direct effects of bFGF have been shown on progenitor cell proliferation (Gabbianelli et al, 1990;Bruno et al, 1993;Gabrilove et al, 1994;Allouche, 1995;Berardi et al, 1995). These direct effects are signi®cantly less than those noted when bFGF is added to stromal based hematopoietic cultures Quito et al, 1996).…”
Section: Discussionmentioning
confidence: 99%
“…bFGF is produced by K562 cells (Allouche, 1995), chronic lymphocytic leukemia cells (Menzel et al, 1996), hairy cell leukemia cells (Gruber et al, 1999) and normal hematopoietic and bone marrow stromal cells (Brunner et al, 1993;Peoples et al, 1995). Increased expression of both bFGF and the FGF type I and type II receptors has been found in CD34 cells from patients who have myelo®brosis with myeloid metaplasia as compared with cells from normal donors (Le Bousse-Kerdil Á es et al, 1996). Signi®cantly elevated levels of bFGF were found in cells from patients with high-risk and intermediate-risk chronic lymphocytic leukemia compared to the levels in cells from those individuals with low-risk disease (Menzel et al, 1996).…”
Section: Bfgf Inhibits Erythroid Differentiationmentioning
confidence: 99%
See 1 more Smart Citation
“…Expression of bFGF and its receptors has been shown in a few other haematological malignancies. In myelofibrosis, an increased production of bFGF has been linked to the fibrotic process (Le Bousse-Kerdiles et al, 1996), whereas serum bFGF levels correlate with clinical stage in B-CLL (Menzel et al, 1996;Aguayo et al, 2000b;Molica, 2001).…”
Section: P-valuementioning
confidence: 99%